Hereditary Hemorrhagic Telangiectasia (HHT) Clinical Trial
Official title:
A Randomised, Placebo Controlled, Double Blind, Multicentre Proof of Concept Study to Assess the Safety and Efficacy of Two Doses of VAD044 in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
The purpose of this Phase 1b proof of concept study, randomised, placebo controlled, double blind, multicentre study is to asssess safety and efficacy of 2 doses of VAD044 in adult HHT patients
After being informed about the study and the potential risks, all patients giving written informed consent will undergo a two months screening and observation period to determine eligibility for study entry. At Day 0, patients who meet the eligibility requirements will be randomized in a double-blind manner (participant and investigator) in a 1:1:1 ratio to 30mg VAD044 (once daily), 40 mg (once daily) or placebo (once daily) ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03397004 -
Doxycycline for Hereditary Hemorrhagic Telangiectasia
|
Phase 2 | |
| Completed |
NCT02936349 -
Graded TTCE for Post-Embolization PAVM Monitoring
|
||
| Completed |
NCT01397695 -
Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
|
Phase 2 | |
| Completed |
NCT01402531 -
Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
|
Phase 2 | |
| Withdrawn |
NCT01406639 -
Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
|
Phase 1 | |
| Completed |
NCT02638012 -
Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT)
|
N/A | |
| Completed |
NCT02464644 -
Frequency of Common Medical Conditions in People With and Without HHT
|
N/A |